2024
Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatients
2019
Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population
Zarour LR, Billingsley KG, Walker BS, Enestvedt CK, Orloff SL, Maynard E, Mayo SC. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. The American Journal Of Surgery 2019, 217: 899-905. PMID: 30819401, DOI: 10.1016/j.amjsurg.2019.01.030.Peer-Reviewed Original ResearchConceptsSolitary hepatocellular carcinomaPrognostic nutritional indexHepatic resectionElderly patientsUnique diseaseLow prognostic nutritional indexMedian Child-Pugh scoreTumor size 5Child-Pugh scoreGrade III complicationsHalf of patientsRecurrence-free survivalSolitary HCCExtrahepatic recurrenceProspective databaseR0 resectionIntrahepatic recurrenceMajor hepatectomyMedian survivalOverall survivalViral hepatitisLow morbidityMedian ageClinicopathologic dataClinicopathologic differences